BUND FINANCE › Stocks › ISRG
Intuitive Surgical, Inc. (ISRG)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +0.08% above its 50-day average.
- It is -1.81% below its 200-day average (long-term downtrend).
- It sits at 34% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$5.7B | US$6.2B | US$7.1B | US$8.4B | US$10.1B |
| Net income | US$1.7B | US$1.3B | US$1.8B | US$2.3B | US$2.9B |
| EPS (diluted) | 4.66 | 3.65 | 5.03 | 6.42 | 7.87 |
| Gross margin | 69.3% | 67.4% | 66.4% | 67.5% | 66.0% |
| Operating margin | 31.9% | 25.4% | 24.8% | 28.1% | 29.3% |
| Net margin | 29.9% | 21.3% | 25.2% | 27.8% | 28.4% |
| Free cash flow | US$1.7B | US$958.4M | US$749.6M | US$1.3B | US$2.5B |
| Total debt | US$87.0M | US$0 | US$0 | US$0 | US$0 |
| Cash | US$1.3B | US$1.6B | US$2.8B | US$2.0B | US$3.4B |
Compound annual growth: revenue 15.2% · net income 13.8% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 50.5x | 72.6x | 27.1x |
| EV / EBITDA | 33.9x | 52.2x | 16.5x |
| Operating margin | 28.4% | — | 3.6% |
| Net margin | 25.5% | — | -0.0% |
| Debt / equity | 0.20 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice